New approach aims to stop dangerous transplant complication
NCT ID NCT02891603
Summary
This study tested whether adding an experimental drug called pacritinib to standard immune-suppressing medications could better prevent graft-versus-host disease (GVHD) after stem cell transplants. The trial involved 40 patients with blood cancers who received matched donor transplants. Participants received the three-drug combination starting around their transplant, with some medications continuing for a year or more to control immune reactions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.